Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Vaxelis Booster in Children
NCT05289271Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Split/Subunit Vaccines
- Countries
- 3
01
Overview
A Phase 4 trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by Merck & Co.. Started Mar 2022; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT05289271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289271.